Skip to main content
Premium Trial:

Request an Annual Quote

ABL, Evivar Strike Cross-license, Marketing Pact

NEW YORK (GenomeWeb News) – Advanced Biological Laboratories has reached cross-license and strategic alliance agreements with Luxembourg-based Evivar, Melbourne, Australia-based ABL said today.

The companies have agreed to develop and commercialize their products, including ABL's TherapyEdge and Evivar's SeqHepB system, for use in management and treatment of HIV and Hepatitis B.

The SeqHepB system is a viral genomics sequence analysis program that is linked to a centralized HBV genomic database. It can be used to identify HBV mutations present in patients and predict their resistance levels to various available medications.

The TherapyEdge is a patient record hospital information system that is used for data and patient management, monitoring, and reporting applications. It also is used for personalized therapy selection, the firms said.

"The combined platforms offer virologists and physicians diagnosing and treating hepatitis and HIV with enhanced clinical and research management tools," Evivar CEO Bernie Romanin said in a statement.

The Scan

Genes Linked to White-Tailed Jackrabbits' Winter Coat Color Change

Climate change, the researchers noted in Science, may lead to camouflage mismatch and increase predation of white-tailed jackrabbits.

Adenine Base Editor Targets SCID Mutation in New Study

Researchers from the University of California, Los Angeles, report in Cell that adenine base editing was able to produce functional T lymphocytes in a model of severe combined immune deficiency.

Researchers Find Gene Affecting Alkaline Sensitivity in Plants

Researchers from the Chinese Academy of Science have found a locus affecting alkaline-salinity sensitivity, which could aid in efforts to improve crop productivity, as they report in Science.

International Team Proposes Checklist for Returning Genomic Research Results

Researchers in the European Journal of Human Genetics present a checklist to guide the return of genomic research results to study participants.